Brensocatib for COVID-19: real-time analysis

Download Image

Post

c19early.org

Brensocatib for COVID-19

1 study with 404 patients

Serious outcome risk

Brensocatib

Control

COVID-19 Brensocatib studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−41%

Mortality (1)−41%

RCTs (1)−41%

Late (1)−41%

00.511.5+

← Brensocatib
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Dec 31 2022	Keir et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00261-2	Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
Dec 31 2022	41% higher mortality (p=0.02) and 39% worse 7-point scale results (p=0.007). RCT 406 hospitalized COVID-19 patients in the UK showing higher mortality and worse clinical status with brensocatib (DPP-1 inhibitor) vs. placebo. Although blood neutrophil elastase activity was reduced, indicating the desired pharmacolo..